Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Identify the Optimal TMS Target to Modulate Reward Activity

Identify the Optimal TMS Target to Modulate Midcingulate Reward Activity in Smokers

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Our primary goal will be to identify the optimal prefrontal-cingulate target by systematically measuring the efficacy of various image-based targeting techniques to increase the reward positivity using the 10-Hz TMS protocol in dependent smokers. Our secondary objective will be to measure the targets' effectiveness to increase decision-making capacity using the probabilistic selection task (PST). Our third objective will be to specifically assess whether the TMS targets has a differential impact on state levels of craving relative to baseline (Tobacco Craving Questionnaire \[TCQ\]. We plan to accomplish these three objectives using a randomized, controlled experiment involving 3 sessions.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Nicotine dependent individuals (according to the Alcohol, Smoking and Substance Involvement Screening Test nicotine dependence score). 2. Be between the ages of 18 and 55 years old. 3. Not received substance abuse treatment within the previous 30 days. 4. Be in stable mental and physical health. 5. If female, test non-pregnant. 6. No evidence of focal or diffuse brain lesion on MRI. 7. Be willing to provide willing to sign a consent form. 8. Be able to comply with protocol requirements and likely to complete all study procedures. Who Should NOT Join This Trial: 1. Contraindication to MRI (e.g., presence of metal in the skull, orbits or intracranial cavity, claustrophobia). 2. Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \> 15 minutes, implanted electronic device, metal in the head, or pregnancy). 3. History of autoimmune, endocrine, viral, or vascular disorder affecting the brain. 4. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment. 5. Life time history of mental disorders such as: Bipolar Affective disorder (BPAD), Schizophrenia, Post-traumatic Stress disorder (PTSD) or Dementia or Major Depression. 6. uninterruptable central nervous system medication Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Nicotine dependent individuals (according to the Alcohol, Smoking and Substance Involvement Screening Test nicotine dependence score). 2. Be between the ages of 18 and 55 years old. 3. Not received substance abuse treatment within the previous 30 days. 4. Be in stable mental and physical health. 5. If female, test non-pregnant. 6. No evidence of focal or diffuse brain lesion on MRI. 7. Be willing to provide informed consent. 8. Be able to comply with protocol requirements and likely to complete all study procedures. Exclusion Criteria: 1. Contraindication to MRI (e.g., presence of metal in the skull, orbits or intracranial cavity, claustrophobia). 2. Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \> 15 minutes, implanted electronic device, metal in the head, or pregnancy). 3. History of autoimmune, endocrine, viral, or vascular disorder affecting the brain. 4. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment. 5. Life time history of mental disorders such as: Bipolar Affective disorder (BPAD), Schizophrenia, Post-traumatic Stress disorder (PTSD) or Dementia or Major Depression. 6. uninterruptable central nervous system medication

Treatments Being Tested

DEVICE

Active 10-Hz TMS to the DLPFC

The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.

DEVICE

Sham TMS-DLPFC

The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.

Locations (1)

Rutgers University - Newark
Newark, New Jersey, United States